Browse the evidence

Obesity initiates the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition.

Understanding the role of obesity in insulin resistance can guide interventions.

Inflammation and fat accumulation are key drivers for losing insulin sensitivity.

Addressing inflammation and fat accumulation may improve insulin sensitivity.

Abdominoplasty following GLP-1 RA-induced massive weight loss shows a trend toward a lower overall complication rate (20% vs 40%) compared to postbariatric surgery.

Practitioners may consider GLP-1 RA therapy as a safer option for patients seeking abdominoplasty after significant weight loss.

Patients taking GLP-1 RAs had superior nutritional status compared to postbariatric patients, indicated by higher albumin and prealbumin levels.

Improved nutritional status in GLP-1 RA patients may enhance surgical outcomes and recovery.

Leptin levels significantly decline following semaglutide treatment, particularly in the obesity group (-5.10 ng/mL).

Semaglutide may help lower leptin levels, which could be beneficial for weight management in diabetic patients.

Adiponectin levels increase significantly post-semaglutide add-on therapy, with the greatest increase in the obesity group (+3.70 μg/mL).

Increased adiponectin levels with semaglutide may enhance metabolic health in diabetic patients.

Long-term mortality was significantly lower in the GLP-1 group (odds ratio 0.58, 95% CI 0.36-0.94).

GLP-1 receptor agonists may improve long-term survival in patients undergoing endovascular treatment for aneurysms.

Obesity is associated with menstrual irregularities, poorer reproductive and obstetric outcomes, and an increased risk of endometrial cancer.

Clinicians should be aware of the reproductive health risks associated with obesity in women.

Both doses of tirzepatide (10 mg and 15 mg) showed significantly greater reductions in predicted diabetes risk compared to placebo.

Practitioners may consider the effectiveness of tirzepatide over placebo in reducing diabetes risk.

Effective weight loss, even when accompanied by gastrointestinal side effects, was associated with a greater willingness to continue Ozempic treatment.

Practitioners should emphasize the importance of weight loss effectiveness in encouraging patients to continue treatment despite side effects.

Semaglutide offers robust cardiovascular protection.

Clinicians can consider semaglutide for patients needing cardiovascular protection in obesity management.

BHB supplementation led to a reduction in LDL cholesterol in the BHB group.

BHB supplementation may improve lipid profiles in overweight and obese individuals.

GLP-1RAs appear to be safe and effective in patients with inflammatory bowel disease (IBD).

Healthcare providers can consider GLP-1RAs as a treatment option for IBD patients.

LLM responses had significantly higher scores than internet responses in the 'objectivity' and 'reproducibility' categories.

Practitioners may consider using LLMs for more objective and reproducible information on GLP1RA therapy.

Current therapeutic strategies for obesity include lifestyle interventions, pharmacologic treatments, and bariatric surgery.

Practitioners should consider a multi-faceted approach to obesity treatment.

Pharmacoeconomic analyses support the cost-effectiveness of combining behavioral, pharmacological, and surgical modalities for obesity treatment.

Integrating various treatment modalities can enhance cost-effectiveness in obesity management.

GLP-1RA users demonstrated significantly reduced pseudarthrosis rates at all time points: 6 months (8% vs. 12%; OR=0.702), 12 months (OR=0.730), and 24 months postoperatively (OR=0.788).

GLP-1RAs may be beneficial in reducing complications like pseudarthrosis in ACDF patients.

GLP-1RAs improve blood pressure regulation and lipid metabolism.

Incorporating GLP-1RAs may enhance management of blood pressure and lipid levels in diabetic patients.

Semaglutide significantly reduced the risk of major limb events (LEs) compared with control interventions, with an odds ratio of 0.70 (95% CI 0.60–0.82; P < 0.0001).

Semaglutide may be an effective treatment option for reducing the risk of PAD-related complications in patients with diabetes or obesity.

The protective effect of semaglutide on limb events was consistent across patient subgroups, including those with diabetes and obesity.

Semaglutide can be considered for diverse populations at risk of PAD.

Weight loss, regardless of the method used to achieve it, is inadvertently accompanied by lean body mass loss, to varying degrees.

Practitioners should be aware that weight loss methods may lead to loss of lean body mass.

The loss of lean body mass, including muscle, is a significant concern associated with weight loss treatments.

Practitioners should monitor muscle mass during weight loss interventions.

Treatment with tesamorelin led to marked reductions in waist circumference and improved lipid levels in a patient with nonobese visceral adiposity.

Tesamorelin may be an effective treatment for reducing visceral fat in specific HIV patients.

Glucagon-like peptide (GLP-1) receptor agonists may induce generalized weight loss but may not effectively target visceral abdominal fat.

GLP-1 receptor agonists may not be the best choice for targeting visceral fat in HIV patients.